Skip to main content
Unknown status

Eloxatin® Plus Gemcitabine Chemotherapy for Mesothelioma

By April 24, 2017No Comments

Condition

Mesothelioma

Estimated Enrollment: 29

Age Group: 18 Years and older   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment

Study ID Numbers: AAAA2861 (Final)

Study First Received: March 9, 2009

Last Updated: January 20, 2012

Estimated Primary Completion Date: March 2009

 

Primary Outcome Measures:

Best Response|Overall Survival|Progression-free Survival

Sponsors and Collaborators:

Columbia University

Website Link: https://ClinicalTrials.gov/show/NCT00859469

Leave a Reply